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Abstract 
Psoralens are often used to treat skin disorders such as psoriasis, vitiligo and others. The 
toxicity and fast degradation of these drugs can be diminished by encapsulation in drug 
delivery systems (DDS). Nanoparticles (NPs) containing the benzopsoralen (BP) (3-
ethoxy carbonyl-2H-benzofuro[3,2-e]-1-benzopiran-2-one) were prepared by the 
solvent evaporation technique, and parameters such as particle size, zeta potential, drug 
encapsulation efficiency, and external morphology were evaluated. The analysis 
revealed that the NPs are spherical and possessed a smooth external surface with 
diameter of 815 ± 80 nm, they present low tendency toward aggregation, as confirmed 
by their zeta potential (+17.3±2.9 mV) and the encapsulation efficiency obtained was 
74%. The intracellular distribution of NPs as well as their uptake by tissues was 
monitored by using laser confocal microscopy and transmission electron microscopy. 
The use of benzopsoralen in association with ultraviolet light (360 nm) revealed 
morphological characteristics of cell damage such as cytosolic vesiculation, 
mitochondria condensation, and swelling of both the granular endoplasmic reticulum 
and the nuclear membrane. The primary target of DDS and drugs in vascular system are 
endothelial cells and an attractive strategy for modifying vascular function in various 
pathological states of skin disorders, cancer and inflammation. The result presented in 
this work indicates that PLGA NP could be a promising delivery system for 
benzopsoralen in connection with ultraviolet irradiation therapy (PUVA) for further 
application in different therapies. 
 
Key words: Nanoparticles; benzopsoralen; vascular endothelial cell; PUVA; 
photochemistry 
 3 
1. Introduction 
The association of psoralens with ultraviolet A (UVA) irradiation (320–400 nm) 
is currently being employed in dermatology (orally or topically) (Ito, Aoshima et al., 
2009; Makki, Muret et al., 1996; Pires, Honda et al., 2004; Stern, 2007; Weber, 
Schmuth et al., 2005). This combination is known as PUVA therapy (Canton, Caffieri et 
al., 2002; Gomes, Faustino et al., 2007; Lysenko, Melnikova et al., 2000; Machado, 
Miranda et al., 2001; Roop, Guy et al., 2004). This treatment is effective against 
diseases such as vitiligo, psoriasis, mycosis fungoides, and atopic eczema, among others 
(Adisen, Karaca et al., 2008; Creamer, Martyn-Simmons et al., 2007; Gambichler, 
2009; Mariano, Vetrano et al., 2002; Saiad, Makki et al., 1997; Serrano-Perez, 
Gonzalez-Luque et al., 2008; Tatchen, Kleinschmidt et al., 2004; Tokura, 1999; 
Wackernagel, Hofer et al., 2006).  
Most psoriasis drug development has focused on the T lymphocyte and its 
cytokines, which have been implicated in the changes seen in the skin of patients with 
psoriasis, including capillary dilation, epidermal ridge dilation, neutrophil proliferation, 
and plaque formation (Baier, Asadullah et al., 2006; Demidem, Taylor et al., 1991; 
Dupuy, Bagot et al., 1991; Giblin and Lemieux, 2006). 
The physicochemical properties of drugs such as molecular weight, shape, charge and 
aqueous solubility determine the rate of diffusion through tissue (Minchinton and 
Tannock, 2006). 
The photophysical properties of the benzopsoralen (BP) (3-ethoxycarbonyl-2H-
benzofuro-[3,2-e]-1-benzopyran-2-one), have been recently investigated (Gomes, 
Lunardi et al., 2007a; Machado, Miranda et al., 2001; Oliveira, Raposo et al., 2003), and 
it has been shown that they can photochemically sensitize the generation of singlet 
oxygen with a quantum efficiency approaching unity (Machado, Miranda et al., 2001), 
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contrary to other compounds (8-methoxypsoralen, 5-methoxypsoralen, 
trimethylpsoralen) (Carter, McMacken et al., 1973; Chen and Lu, 1999; Collins, 
Wainwrigth et al., 1996; Legat, Wolf et al., 2001; Man, Dawe et al., 2004) usually 
employed in PUVA therapy. Unfortunately, most photosensitizing chemicals are also 
phototoxic to the skin, and skin contact with these molecules in the presence of UV 
irradiation results in sunburn, erythematic, and eventual edema (Middelkamp-Hup, 
Pathak et al., 2004; Roop, Guy et al., 2004), thus limiting the use of PUVA therapy for 
the treatment of skin disorders (Gomes, Faustino et al., 2006; Lindelöf, Sigurgeirsson et 
al., 1999; Middelkamp-Hup, Pathak et al., 2004).  
A drug delivery system (DDS) may be used to enhance the action of PUVA 
therapy in special nanoparticles have been investigated for the delivery of different 
types of therapeutic agents including proteins, peptides, and DNA (Labhasetwar, 
Bonadio et al., 1999; Labhasetwar, Song et al., 1997). In addition to providing sustained 
release, nanoparticles can protect the encapsulated agent from enzymatic degradation 
(Alexis, 2005; Hedley, Curley et al., 1998; Yoshioka, Kawazoe et al., 2008). Since 
PLGA is a biodegradable and biocompatible polymer, it is well tolerated by the body 
and cells (Mooney, Sano et al., 1997; Wischke and Schwendeman, 2008; Yang, Li et 
al., 2009). 
It is well known that endothelium is an important target for drugs because it is 
involved in a number of normal and pathophysiological conditions such as 
angiogenesis, atherosclerosis, tumor growth, myocardial infarction, limb and cardiac 
ischemia, restenosis, etc (Dass and Su, 2000; Davda and Labhasetwar, 2002; Martin and 
Murray, 2000; Parikh and Edelman, 2000). In skin disorders such as psoriasis there is 
now considerable evidence indicating that angiogenesis may, at least in part, play a role 
in increasing the psoriatic plaque (Hern, Stanton et al., 2005). Also the demonstration of 
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angiogenic activity in plaque skin has led some authors to investigate the possible 
benefits of antiangiogenic agents in the treatment of clinical lesions (Atherton, Wells et 
al., 1980; Dupont, Falardeau et al., 2002). However, the delivery of agents that induce 
destruction of the endothelial cells in skin vasculature, activated by light irradiation 
need to be investigated. Thus, the main objective of this work is to evaluate the 
morphological changes of vasculature in the rat skin after NP-BP with light irradiation. 
In this work we analyzed the rat skin and the mimetic vessel like a rat aorta to 
understand the uptake of the NP-BP by endothelial cell by using transmission electron 
microscopy and confocal microscopy. 
 
2. Material and Methods 
2.1. Chemicals 
Poly(D,L-lactic-co-glycolic acid) (PLGA) 50:50, Mw 17 kDa (Sigma), polyvinyl alcohol 
(PVA) (13-23 kDa, 87-89% hydrolyzed) (Aldrich), and analytical grade 
dichloromethane (Merck) were used as supplied. The fluorescent bezopsoralen 3-ethoxy 
carbonyl-2H-benzofuro[3,2-e]-1-benzopiran-2-one (BP) was synthesized and supplied 
by Oliveira-Campos, from Minho University. All other chemicals were of analytical 
grade and were used without further purification. 
 
2.2. Preparation of nanoparticles by the solvent evaporation technique 
The NPs loaded or not with BP were prepared by solvent evaporation method (Gomes, 
Assuncao et al., 2007; Gomes, Lunardi et al., 2005). Typically, the organic phase 
consisted of 0.1 g of the PLGA 50:50 polymer and 10 mM of fluorescent BP dissolved 
in 10 mL of CH2Cl2. The dispersed phase was dropped into the homogeneous aqueous 
phase (50 mL of an aqueous phase containing 1% (w/v) of 88% hydrolyzed PVA as 
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dispersing agent) under ice cooling, using a high speed homogenizer (Ultra-Turrax T18-
S18N-19G, IKA) for 60 s, at 14,000 rpm. Further solvent evaporation was carried out 
by gentle magnetic stirring at room temperature, for a period of 3–5 h. NP was 
recovered by centrifugation for 5 min, at 10,000 rpm and 4 ◦C. They were then washed 
(three times) with distilled water and lyophilized (Labconco®, USA). NP without BP 
was prepared by the same procedure. Dried NP was stored in a sealed glass vial and 
placed in a dessicator kept at 4 ◦C. 
 
2.3. Particle size and Surface Charge (Zeta Potential) 
Particle size and size distribution were determined by photon correlation spectroscopy 
(PCS) using the quasi-elastic light scattering technique, in a Zetasizer 3000 equipment 
(Malvern Instrument) equipped with a 10 mW He-Ne 633 nm laser beam, at 25oC and at 
a scattering angle of 90°. For the particle size analysis, a dilute suspension (1.0 mg/mL) 
of NP was prepared in double distilled water and sonicated in an ice bath for 30 s. The 
zeta potential of the NPs in PBS buffer, (0.1mM, pH 7.4 1.0 mg/mL) was determined by 
using ZetaPlusTM in the zeta potential analysis mode. 
 
2.4. Encapsulation efficiency 
A weighed quantity of NPs was dissolved in methylene chloride. The BP content was 
assayed by spectrometry at 345 nm by using a calibration curve. The calibration curve 
for the quantification of BP
 
was linear over the range of standard concentration between 
1x10-7 a 1x10-3 mol.L-1 with a correlation coefficient of R2 =1.0. The encapsulation 
efficiency was calculated as following (Equation 1): 
100 
drug ofamount  Initial
clemicropartiin  drug ofAmount (%) efficiencyion Encapsulat ×=   (Equation 1) 
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2.5. Nanoparticles Morphology: SEM Analysis 
Scanning electron microscopy (SEM) was used to evaluate the shape of PLGA NPs. 
Samples were washed with sterile distilled water, fixed in 2.5% (v:v) glutaraldehyde 
(GA) in water, for 2 hours, washed again with water, dehydrated in a graded ethanol 
series and critical point dried. Samples containing NPs were mounted on aluminum 
stubs and due to their lack of electrical conductivity, coated with 50 nm gold coating 
under an argon atmosphere. NPs were examined and photographed using a EVO 50 
(Zeiss) Scanning Electron Microscope operating at 20 kV in the traditional mode (SE1 
detector). 
 
2.6. Skin 
Male Wistar rats weighing approximately 150 g (n= 4) were anaesthetized with a 
mixture of halothane, N2O and O2. After shaving and disinfection, 200 µL of a 25% 
suspension of BP-NP in 10 mM PBS, pH 7.4, was injected subcutaneously. At day 2 the 
rats were sacrificed and the NPs with surrounding tissue, skin, and underlying muscle 
were carefully dissected. The samples were fixed in either of the fixative agents already 
described, during the time shown in brackets: formalin 4% (24 h); or mixture of 
formalin (4%) plus glutaraldehyde (0.1%) in PBS (12 h); or glutaraldehyde (2.5%) in 
PBS (6 h). After fixation the samples were processed for microscopy analysis. 
 
2.7. Transmission electron microscopy (TEM) 
For the TEM studies, the samples were fixed in 2.5% glutaraldehyde in 0.1 mol.L-1 
sodium cacodylate buffer (pH 7.4) for 2h, at 25◦C. The fixed cells were then post fixed 
in 1% osmium tetroxide in the same buffer for 1 h, dehydrated in a graded acetone 
series, and embedded in epoxy resin. Ultrathin sections were contrasted with alcoholic 
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2% uranyl acetate and 5% lead citrate. Ultrastructural examination was performed with 
a transmission electron microscope Philips CM-100 (Philips Electron Optics, 
Eindhoven, The Netherlands). 
 
2.8. Visualization of cellular uptake by confocal laser scanning microscopy 
Male Wistar rats (400- 450 g) were killed by decapitation and all the procedures are in 
accordance with the Ethical Animal Committee of the University of São Paulo, Brazil. 
The thoracic aorta was quickly removed, cleaned of adherent connective tissues, and cut 
into rings (100 ± 20 µm thick). To image arterial cross sections, the aorta rings were 
placed vertically in a coverslip covered with poly-L-lysine. The tissue was loaded with 
fluorescent BP-NP by incubation in the normal Hanks solution 120 min in CO2 
incubator. After washing with Hanks solution, the segment was placed on a chamber 
(1.0 mL in volume). The chamber was placed on the stage of a confocal microscope 
from the bottom of the chamber through a water-immersion objective (63X). Excitation 
wavelengths and emission was set according to the fluorescence properties of the drug 
(Ex. 488 nm / Em. 532 nm) 
 
2.9. Irradiation 
BP-loaded nanoparticles (20 mg) were re-constituted with 2.0 mL of PBS pH 7.4 with 
0.1% w/v Tween 80 in a glass vial which was shaken and briefly bath-sonicated. 1.5 mL 
of this suspension was then subcutaneously administered into the dorso lateral region of 
the neck. After 2 hours the region was irradiated using a 400-W mercury arc lamp was 
used as the irradiation source. A pass-band filter (Ocean Optics U360) filtered the 
radiation, ensuring the samples were irradiated with light of 360 ± 10 nm (maximum 
transmittance 69%). Typical irradiances of 0.030 to 0.035 W/cm2 were used to deliver a 
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fluency of 1.0 J/cm2. The irradiances were quantified using a PMA 2100 solar light 
radiometer. After light treatment, the cells were kept in the dark for 2 hr. Nonirradiated 
cells were kept in the dark for the same period of time. The ambient light was <0.001 
mW/cm2. Both irradiated and nonirradiated cells were processed by TEM. 
 
2.10. Statistical analysis 
Statistical analysis of the results was carried out using Student’s t-test. 
 
3. Results  
3.1. Nanoparticles Morphology: SEM Analysis  
The morphological analyses of the NPs were performed using scanning electron 
microscopy (SEM). Figure 1A shows a representative micrograph of a benzopsoralen-
loaded nanoparticles, magnified at 20,000x. In all preparations reported in this paper the 
particles are spherical in shape, displaying a smooth surface. No meaningful difference 
was found between benzopsoralen loaded PLGA nanoparticles and the empty 
nanoparticles used as control. Figure 1B shows a laser scanning confocal microscopy of 
benzopsoralen loaded PLGA nanoparticles excited with 488nm. 
FIGURE 1  
 
3.2. Particle size and surface charge (zeta potential) 
The distribution analyses (DLS) show a uniform size with varying diameters from 720 
to 930 nm as presented in Figure 2 and confirmed by Figure 1. 
 
FIGURE 2  
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The NPs colloidal stability was analyzed by measuring the NP zeta potential. In theory, 
more pronounced zeta potential values, either positive or negative, tend to stabilize 
particle suspension, since the electrostatic repulsion between particles with the same 
electric charge prevents aggregation of the nanoparticles. The particles consisting of 
PLGA-free dye were negatively charged (−3.2mV at pH 7.4) whereas the zeta potential 
measured for the NPs loaded with benzopsoralen was +17.3 ± 2.9 mV.  
 
3.3. Encapsulation Efficiency 
The drug entrapment efficiency parameter was calculated from the experimentally 
determined actual drug loading of the NP and the theoretical drug loading. The values 
obtained by this method 74±4% of incorporation. 
 
3.4. Transmission electron microscopy (TEM) analysis 
The histological evaluation of the vascular endothelial cells loaded with NP-PB 
with/without UVA irradiation was done by TEM. In Figure 3A it is presented the 
transversal cut of the control rat skin without the nanoparticle and irradiated with light 
at 360 ± 10 nm showing the intact vessel (black arrow-endothelial cell, star-myofibrils 
of muscle cell and bold arrow-muscle layer). In Figure 3B it is displayed the endothelial 
and muscle cells loaded with NP-BP without light irradiation. This image shows no 
alteration in the cytoplasm of the endothelial cell. In Figure 3C it is shown the damage 
in the cytoplasm of endothelial cell promoted by activation of NP-PB by irradiation ( 
black arrow). 
 
FIGURE 3  
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3.5. Laser Confocal Microscopy and image analysis 
The uptake of NP-BP by endothelial cells was evaluated in aorta rings as a model 
incubated for 120 minutes and imaged with a confocal microscope. As shown in Figure 
4A, phase contrast image of the aorta ring segment has undulation of the internal elastic 
membrane, which exists between vascular smooth muscle cells (VSMC-square) and 
endothelial cells (ECs-circle) layers. The endothelial layer with the uptake BP-NP 
(arrows) were imaged in xyz mode 1024x1024 pixel at 700Hz by a confocal scanning 
laser microscope (Leica TCS SP5). The BP-NP fluorescence was excited with the 488 
nm line of an argon ion laser and the emitted fluorescence was measured at 490-550 nm 
as shown in Figure 4B. Serial z-sections of the cells, each 1 µm in thickness, 
demonstrated fluorescence activity in all the sections between 10 and 25 µm from the 
surface of the cells indicating that the nanoparticles were internalized by the cells and 
not simply bound to their surface (Figure not shown). Nanoparticles were mostly seen 
localized in the EC as showed in merged image (Figure 4C). 
A major advantage of using the rat aorta artery segment was that SMCs and ECs were 
observed simultaneously at one confocal plane.  
 
FIGURE 4   
 
4. Discussion 
The benzopsoralen was encapsulated in polymeric nanoparticles of PLGA using 
the solvent evaporation technique. The choice of loading conditions was dictated by the 
characteristics of both BP and the NPs matrices. The BP is a hydrophobic compound 
with low molecular weight which makes it able to be used with the PLGA polymer. 
This polymer is biocompatible and biodegradable and also has been approved by the 
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FDA for certain human clinical uses (Gomes, Lunardi et al., 2006a; Gomes, Lunardi et 
al., 2006b; Jain, 2000; Khang, Rhee et al., 2003; Sinha and Trehan, 2005; Thomas, 
Dean et al., 2006). 
The morphological analysis of the nanoparticles was performed using SEM. In 
all preparations reported in this paper the particles are spherical in shape, displaying a 
smooth surface. No meaningful differences were found between the PLGA 
nanoparticles containing benzopsoralen (BP-NP) and the empty PLGA nanoparticles 
used as control in relation to external morphology. Similar behavior has been described 
in relation to external morphology using different drugs loaded into nano and 
microparticles when the solvent evaporation technique was applied (Gomes, Assuncao 
et al., 2007; Gomes, Faustino et al., 2007; Gomes, Faustino et al., 2006). 
The success of this process depends primarily on the retention of the hydrophilic 
active compound within the polymer-containing organic phase from which the matrix is 
formed after evaporation of the solvent (Gomes, Barbougli et al., 2008; Gomes, Lunardi 
et al., 2007b). The parameter indicative of this behavior is the entrapment efficiency. 
The high value (74%) of the BP entrapment efficiency for the NP is consistent with the 
hydrophobic character of the compound. 
According to the literature (Jeon, Jeong et al., 2000), the administration of 
particles with a diameter of several micrometers (larger than 6.0 µm) seems to be 
inefficient as a drug delivery system (DDS) because of its accumulation in lung 
capillaries and its difficult removal from the endothelial reticulum system (Gomes, 
Lunardi et al., 2006a; Jeon, Jeong et al., 2000).The particle size significantly affects the 
level of cellular and tissue uptake, and in some cell lines, only submicron size particles 
are efficiently taken up (Gomes, Faustino et al., 2006; Panyam and Labhasetwar, 2003). 
In this respect, the size of particles is important and should be characterized carefully. 
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The particles loaded with BP, evaluated by DLS, showed minimum dispersion size. 
Therefore, this method resulted in the preparation of particles, suitable for the use as a 
DDS. 
The skin consists of five layers (deepest to most superficial): the stratum basale, 
the stratum spinosum, the stratum granulosum, the stratum lucidum, and the stratum 
corneum. It is also composed of four different types of cells: keratinocytes, 
melanocytes, Langerhan’s, and Merkel cells (Peters, Weissman et al., 2000). Typically, 
it takes about four weeks for cells to move from the stratum basale toward the stratum 
corneum (Peters, Weissman et al., 2000). The keratinocytes in the basal layer divide 
once every 13 to 14 days (Greaves and Weinstein, 1995; Peters, Weissman et al., 2000). 
The surface cells slough off and are replaced by the underlying cells. In psoriatic skin, 
the cell cycle accelerates and the cells divide every 1.5 days, with maturation and 
shedding occurring in four days. Since the cells move to the surface so rapidly, they do 
not differentiate, thus forming scaly, inflamed, red skin (Greaves and Weinstein, 1995; 
Peters, Weissman et al., 2000). 
Most psoriasis drug development has focused on the T lymphocyte and its 
cytokines, which have been implicated in the changes seen in the skin of patients with 
psoriasis, including capillary dilation, epidermal ridge dilation, neutrophil proliferation, 
and plaque formation. Transmission electron microscopy (TEM) demonstrates that the 
drug was entrapped in the NP and that it was able to successfully promote efficient 
photodamage in the target tissue and cells of PUVA therapy. The cellular uptake was 
also visualized by confocal microscopy. The BP shows a fluorescence emission at 532 
nm and the NP-BP was uptaked by endothelial cells. 
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5. Conclusions 
In this study, the hydrophobic compound (3-ethoxy carbonyl-2H-benzofuro[3,2-e]-1-
benzopiran-2-one) was encapsulated in a biodegradable polymer matrix (PLGA) to 
generate stable nanoparticles. The present study demonstrates that the solvent 
evaporation method is a simple and suitable technique for the encapsulation of the 
hydrophobic compound, showing high encapsulation efficiency. The results displayed a 
good batch to batch reproducibility with respect to the particle characteristics (size and 
size distribution, encapsulation efficiency and release profile).  
In summary, the results of this study suggest that the nanoparticle prepared with PLGA 
may provide a sustained drug-delivery system that can be used in order to obtain a local 
and systemic effect with no drug-related side-effect. Further studies are necessary to 
standardize the local tissue dose and the systemic prolonged exposure with maximal 
antineoplasic activity and minimal side-effect. 
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